If you are looking to gain exposure to the beaten down tech sector, then it could be worth considering the two stocks in this article.

That’s because they have been named as buys and are tipped to rise strongly from current levels. Here’s what is being recommended:

Pro Medicus Ltd (ASX: PME)

The first ASX 200 tech stock that could be a buy is Pro Medicus.

It is a healthcare technology company with a specialised focus. Its Visage imaging platform is used by hospitals to process and analyse medical images quickly and efficiently.

The company has built a strong position in the United States, where it continues to win long-term contracts with major healthcare providers. These agreements provide visibility over future revenue and support high margins.

Demand for more efficient medical imaging is growing, particularly as data volumes increase in healthcare systems and radiologist shortages persist.

With a proven product and expanding customer base, Pro Medicus continues to show how specialised software can scale globally.

Morgans recently put a buy rating and $210.00 price target on its shares. Based on its current share price of $134.84, this implies potential upside of more than 55% over the next 12 months.

Putting that in context, a $10,000 investment in Pro Medicus shares would become approximately $15,500 if Morgans’ recommendation proves accurate.

Xero Ltd (ASX: XRO)

Another ASX 200 tech stock that could rise strongly is Xero.

It provides cloud-based accounting software to small and medium-sized businesses. Its platform sits at the centre of financial operations, making it a key tool for managing accounts, payroll, and payments.

The company’s growth opportunity remains significant. There are still many businesses globally that have yet to adopt cloud accounting solutions, and Xero continues to expand its presence in markets such as the United States.

It is also building out additional services, including payments and financial insights, which can increase revenue per user over time.

With a large market opportunity and multiple ways to grow, Xero remains well placed to expand over the long term.

UBS is bullish on this ASX 200 tech stock. The broker recently put a buy rating and $127.00 price target on Xero’s shares. Based on its current share price of $79.30, this implies potential upside of 60% for investors between now and this time next year.

To put that into context, a $10,000 investment would turn into approximately $16,000 if UBS is on the money with its recommendation.

The post These beaten down ASX 200 tech stocks could rise 55% to 60% appeared first on The Motley Fool Australia.

More reading

• 3 super cheap ASX 200 shares I’d buy right now
• 3 ASX healthcare shares to buy amid sector rout: experts
• 3 reasons to buy Pro Medicus shares today
• Could buying Xero shares at $80 make me rich?
• These ASX 200 shares could rise 25% to 70%

Motley Fool contributor James Mickleboro has positions in Pro Medicus and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

As May approaches, investors are no doubt looking for opportunities that reflect both recent market moves and longer-term trends.

Some areas have been sold off and could be setting up for a recovery. Others continue to benefit from structural growth or offer exposure to high-quality businesses.

Here are three ASX exchange traded funds (ETFs) that stand out for different reasons.

BetaShares S&P/ASX Australian Technology ETF (ASX: ATEC)

The first ASX ETF to look at is the BetaShares S&P/ASX Australian Technology ETF.

It has been caught up in the broader weakness across technology shares this year. That has pushed valuations lower across a number of its holdings, despite their underlying businesses continuing to execute.

Its portfolio includes companies such as NextDC Ltd (ASX: NXT), Pro Medicus Ltd (ASX: PME), and REA Group Ltd (ASX: REA).

With sentiment around tech currently subdued, the BetaShares S&P/ASX Australian Technology ETF offers a way to gain exposure to a group of companies that are still tied to structural growth, but trading on lower multiples than a year ago. This fund was recently recommended by analysts at BetaShares.

Betashares Global Cash Flow Kings ETF (ASX: CFLO)

Another ASX ETF worth looking at in May is the Betashares Global Cash Flow Kings ETF.

This fund focuses on companies that generate strong and consistent free cash flow. Rather than chasing emerging themes, it leans toward businesses with established earnings and the ability to reinvest over time.

Its holdings include companies such as Alphabet (NASDAQ: GOOG), Mastercard (NYSE: MA), and Palantir Technologies (NASDAQ: PLTR).

Alphabet is a good example of this approach. Its core search business produces significant cash flow, which supports continued investment in areas like artificial intelligence and cloud computing. That financial strength allows it to expand without needing to rely heavily on external funding. It was also recently recommended by analysts at BetaShares

BetaShares Global Cybersecurity ETF (ASX: HACK)

A third ASX ETF to consider in May is the BetaShares Global Cybersecurity ETF.

Cybersecurity has become a core requirement for businesses as more systems move online and digital threats become more sophisticated.

Its holdings include companies such as Cisco (NASDAQ: CSCO), Palo Alto Networks (NASDAQ: PANW), and Okta (NASDAQ: OKTA).

Okta is a good example of how the sector is evolving. It focuses on identity and access management, helping organisations control who can access systems and data. As businesses adopt more cloud-based tools, this type of service becomes increasingly important.

With demand for cybersecurity continuing to build, the future looks bright for the BetaShares Global Cybersecurity ETF and its holdings.

The post Why these ASX ETFs could be top picks in May appeared first on The Motley Fool Australia.

More reading

• After 7 straight days in the red, where is the value for ASX 200 stocks?
• Are these the best ASX ETFs to buy in May?
• 3 excellent ASX ETFs to buy and hold for 10 years or more
• Why it’s time to look past the “SaaSpocolypse” and target Aussie tech
• Is this ASX ETF the perfect companion to Vanguard’s VAS?

Motley Fool contributor James Mickleboro has positions in Nextdc, Pro Medicus, and REA Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, BetaShares Global Cybersecurity ETF, Cisco Systems, Mastercard, Okta, and Palantir Technologies. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Palo Alto Networks and Pro Medicus. The Motley Fool Australia has recommended Alphabet, Mastercard, Okta, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It’s currently the season for quarterly reports, which tends to also be a good time to see what the brokers are saying about companies which have reported, or are just about to.

I’ve selected three reports from Macquarie on companies which fit the bill, two of which reported just in recent days.

So let’s have a look what they’re saying.

Whitehaven Coal Ltd (ASX: WHC)

This week, Whitehaven Coal released its quarterly report. The company revealed it had generated sales of 6.8 million tonnes of coal for the March quarter, broadly in line with the December quarter.

But while production was flat, the company received better prices for both its metallurgical and thermal coal. Given the continued troubles in the Middle East, this is expected to continue.

As the company said:

Long-term demand for seaborne high caloric value thermal coal, together with a structural supply shortfall from underinvestment in new mines and depletion of existing supply, remains a driver for longer-term price support for high caloric value thermal coal. In developing economies, thermal coal continues to play a critical role in delivering affordable and reliable access to electricity. This focus on energy security is expected to further support long-term demand for high-quality thermal coal. Disruptions are likely to continue to impact supply across the global energy complex for a period following cessation of Middle East tensions.

Macquarie has a price target of $9.75 on Whitehaven shares, compared with $8.28 currently.

Aurelia Metals Ltd (ASX: AMI)

Also this week, Aurelia Metals reported gold production of 13,000 ounces for the quarter, and that it had increased its cash balance from $85.6 million at the end of December to $94.7 million at the end of March.

Aurelia also increased its full-year production guidance, saying gold production was now expected to come in at 45,000 to 50,000 ounces, compared with the previous guidance of 35,000 to 40,000 ounces.

Forecast copper production, however, reduced from 3,000 to 4000 tonnes to 2.5-3000 tonnes.

Macquarie said in its research note on the company that gold production came in 17% higher than consensus estimates, although the company’s base metals production was weak.

Macquarie maintained its price target of 40 cents on the company’s shares. This is materially above its current share price of 31 cents, which increased 9.8% on Wednesday.

Amcor Ltd (ASX: AMC)

Amcor is yet to report its quarterly results, which are scheduled to come out on May 6, however Macquarie has put out a research note in advance.

The broker said they were expecting $200-$250 million in adverse working capital movements from an increase in raw materials costs, “which is likely to reduce AMC’s $1.8-$1.9 billion full year free cash flow guidance”.

Macquarie has reduced their earnings per share assumptions and therefore reduced their price target on Amcor from $86.50 to $84.63, however this is still well above the current share price of $54.13.

The post Macquarie names 3 ASX shares to buy appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Should you buy Coronado Global and Whitehaven Coal shares?
• Why 29Metals, Aurelia Metals, Codan, and oOhMedia shares are racing higher today
• What are Whitehaven Coal shares worth following their quarterly results? 2 Brokers have their say
• 2 brokers rate this ASX gold stock a buy, with 50% upside forecast

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Amcor Plc and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) and many ASX shares endured yet another red session this hump day, its third in a row this week, and seventh in total. By the time trading wrapped up, the ASX 200 had slid another 0.27% lower, leaving the index below 8,700 points at a flat 8,687.

This rather woeful Wednesday for the local markets comes after a similarly downbeat night over on the American stock exchanges.

The Dow Jones Industrial Average Index (DJX: .DJI) managed to snatch a loss from the jaws of victory, losing 0.053%.

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) was more decisive, though, dropping 0.9%.

But let’s get back to ASX shares and assess the damage from today’s trading amongst the different ASX sectors.

Winners and losers

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• Should you buy Coronado Global and Whitehaven Coal shares?
• Why 29Metals, Aurelia Metals, Codan, and oOhMedia shares are racing higher today
• Why is this ASX gold stock slipping despite new gold discoveries?
• Why did the ASX 200 just rebound following the hottest inflation print since 2023?
• A big milestone for this ASX biotech. Here’s why the share price is moving

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

APA Group (ASX: APA) shares have climbed another 0.6% to a three-year high of $10.18 at the time of writing. 

The latest increase means the shares are now 13% higher for the year-to-date, having rebounded nearly 19% since mid-January. APA shares are now also 22% higher than 12 months ago.

Why are APA shares climbing higher?

There is no price-sensitive news out of APA recently to explain the latest share price surge. The share price hike is likely the result of investors increasingly rotating into defensive income-generating shares during ongoing volatility.

APA is Australia’s largest energy infrastructure company, owning and operating an extensive portfolio of gas, electricity, solar, and wind assets.

The company is also a major owner and operator of Australia’s gas distribution network, including pipelines, gas-fired power stations, and storage facilities. It transports more than half the natural gas used in Australia. 

Since listing on the ASX in 2000, APA Group has substantially grown its energy assets. More recently, it has added solar farms to its portfolio. 

APA announced its latest expansion plans in February, around the same time it posted an impressive first-half FY26 result.

APA posted a 7.6% jump in underlying EBITDA to $1,092 million and upgraded its organic growth pipeline from $2.1 billion to around $3 billion for FY26 to FY28.

FY26 Underlying EBITDA guidance is unchanged at $2,120–$2,200 million, with expectation to exceed midpoint.

The company also said it is on track to achieve $50 million in full-year cost savings, helped by simplification efforts including the sale of its Networks business and pending divestment of its GDI stake.

It’s this continued long-term revenue which means the company is able to pay a consistent passive income to its shareholders too.

APA paid an interim dividend of 27.5 cents in the first half of FY26 and is guiding a full-year dividend of 58 cents per security. That translates to a forward distribution yield of 5.7%, partially franked, at the time of writing.

Are the shares a buy, sell or hold now?

Despite the latest share price rally, and the company’s attractive passive income, analysts aren’t too optimistic about the outlook for APA shares over the next 12 months.

According to TradingView data, four out of nine analysts have a hold rating on the stock, three have a sell or strong sell rating. Others are more bullish with a buy or strong buy rating.

But, the average target price for APA shares is $8.96, which implies a potential 12% downside at the time of writing.

Even the best-case scenario $10.41 maximum target price implies a minor 3% upside from the current trading price. 

The post Are APA shares a buy after reaching a three-year high? appeared first on The Motley Fool Australia.

More reading

• 3 top ASX income ideas beyond CBA and the big four banks
• Want to build up a second income? These 2 top ASX shares are a buy
• 3 ASX dividend shares I’d hold through anything
• 5 powerhouse ASX dividend shares to buy and hold until 2050
• 3 ASX 200 shares tipped to tumble 10% (or more) in the next 12 months

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Apa Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two of the largest coal miners on the Australian share market have released updates this week.

Bell Potter has been running the rule over these updates from Coronado Global Resources Inc (ASX: CRN) and Whitehaven Coal Ltd (ASX: WHC). But has it seen enough to recommend either coal miner as a buy?

Let’s see what the broker is saying about them:

Coronado Global Resources

Bell Potter notes that it was a challenging first quarter for Coronado, with production and sales down heavily quarter on quarter, and costs coming in higher than expected. It said:

CRN reported quarterly saleable coal production of 3.0Mt (down 30% QoQ; BPe 3.3Mt) and sales of 3.5Mt (down 20% QoQ; BPe 3.3Mt). Production was heavily impacted by a 6-week shutdown at Mammoth following a fatality; adverse weather and a planned 2-week CHPP shutdown at Curragh; and two longwall moves at Buchanan. Group mining costs were US$135/t produced (BPe US$113/t), up 41% QoQ. Group realised met coal pricing was US$165/t (70% realisation to the average HCC index). BP calculated quarterly group EBITDA was -US$88m (BPe US$8m) with unit mining costs elevated on lower sales.

In response, the broker has retained its speculative hold rating with a reduced price target of 30 cents.

Whitehaven Coal

Unlike Coronado Global, Bell Potter notes that Whitehaven Coal performed better than feared during the third quarter. It highlights that production and sales were ahead of expectations for the three months. The broker said:

WHC reported quarterly managed ROM production of 9.5Mt (BPe 9.6Mt), managed saleable production of 8.4Mt (BPe 7.8Mt) and equity coal sales of 6.9Mt (BPe 6.3Mt). Sales were supported by a stock drawdown with production impacted by heavy rainfall in Queensland and geotechnical issues at Narrabri. The next 8-week longwall changeout and maintenance period is scheduled for the December 2026 quarter. Group realised pricing was A$207/t, up 9% QoQ in line with higher met and thermal market prices. FY26 guidance was reiterated; ROM production and sales are tracking to the upper end and costs to the middle of the ranges provided.

According to the note, the broker has retained its hold rating and $8.10 price target on Whitehaven Coal’s shares.

Bell Potter then concludes:

We maintain a Hold recommendation. In the medium term, WHC are positioned to capitalise when coal markets sustainably improve with a diversified portfolio of assets in Queensland and New South Wales and strong organic growth optionality. We have a positive long term met coal outlook, driven by constrained supply and increased demand from steel producers reliant on seaborne met coal (i.e. India).

The post Should you buy Coronado Global and Whitehaven Coal shares? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• What are Whitehaven Coal shares worth following their quarterly results? 2 Brokers have their say
• 5 things to watch on the ASX 200 on Wednesday
• Here are the top 10 ASX 200 shares today
• Why is everyone talking about Whitehaven, Deep Yellow and Beach Energy shares on Tuesday?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Vitrafy Life Sciences Ltd (ASX: VFY) shares have been strong performers this year.

During this time, the ASX stock has risen over 60%.

But if you thought you were late to the party, think again.

That’s because Bell Potter believes the life sciences company’s shares could continue to rise over the next 12 months.

What is this ASX stock?

Vitrafy is aiming to become a global leader in cryopreservation by significantly improving cell survival of biological materials.

The ASX stock has designed and developed an innovative solution for the advancement of cryopreservation which includes smart devices, a quality management software platform, and smart packaging solutions.

Bell Potter highlights that after 18 months as a listed company, Vitrafy is approaching an inflection point. It said:

It has been c.18 months since the IPO and VFY are now approaching the point where commercial revenues are within reach. The final report on the Phase II USAISR study is due to be released in 4Q26, with an understanding that the study has been successful and passed regulatory standards.

An update on commercial activity with USAISR is expected in 1H27. The market would be hoping for a final commercial agreement. This collaboration is understood to have created material inbound interest from the civilian blood products sector and follows a recent end-of-life announcement for a legacy technology. No details were provided but this event could be a catalyst for demand for VFY’s liquid nitrogen free cryopreservation technology.

Big potential returns

According to the note, Bell Potter has retained its speculative buy rating on the ASX stock with a significantly improved price target of $3.00 (from $2.25).

Based on its current share price of $2.10, this implies potential upside of 42% for investors over the next 12 months.

While Bell Potter still has a speculative rating on the stock, it notes that it has removed a 10% risk rating in response to operational progress. It concludes:

We judge the progress VFY has made in blood products and animal production to be sufficient to remove the 10% risk rating we had applied to our revenue forecasts, lifting our FY27e/FY28e revenue estimates by c.11%. Subsequently, this lifts our DCF valuation by c.33% to $3.00/sh.

Since the post IPO low of $1.08 a year ago, VFY’s share price has effectively doubled as confidence toward commercialisation has increased. Key catalysts relate to 1) securing commercial arrangements with USAISR and 2) FDA registration for the Guardion cryopreservation device.

The post Up 60%: Why this exciting ASX stock could keep rising appeared first on The Motley Fool Australia.

More reading

• What are brokers saying about these ASX shares hitting 52-week highs

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

4DMedical Ltd (ASX: 4DX) shares are falling again on Wednesday, with the high-growth stock extending losses despite no new update.

At the time of writing, the 4DMedical share price is down a sizeable 9.34% to $4.27.

That follows a 5.23% drop yesterday and leaves the stock down more than 20% over the past week.

There has been no announcement to explain the move, which points to broader forces at play.

Let’s take a closer look.

Selling builds after massive run

The recent pullback comes after an extraordinary run for the stock.

4DMedical shares are still up more than 1,300% over the past 12 months, even after this week’s decline. The company’s market capitalisation sits around $2.5 billion, and it remains in the S&P/ASX 200 Index (ASX: XJO).

That surge was driven by growing interest in its lung imaging platform, alongside regulatory wins and commercial progress in the United States.

But when a stock moves that far, that fast, it tends to attract a lot of short-term interest.

Day traders often pile in during the sharp rally. But when momentum fades, they can exit just as quickly to lock in profits.

And that can amplify the downside, especially when buying support is limited.

Tech sector weakness adds pressure

The broader backdrop is not helping.

The S&P/ASX All Technology Index (ASX: XIJ) is down 4.18% over the past week and has fallen roughly 20% over the past 12 months.

This shows that the selling is not limited to one stock.

Growth shares have been under pressure as investors rotate away from higher-valuation companies, which has been noticeable over the last few sessions.

The ASX 200 Index has also been drifting lower. It is down about 2.93% over the past week and is trading around 8,687 points today.

Valuation and expectations in focus

4DMedical is still in its growth phase.

It is building out its commercial footprint and pushing for wider adoption of its imaging technology. That includes contracts, regulatory approvals, and hospital rollouts.

The trade-off is that earnings remain limited. The company is not profitable yet, and that could take time as it continues to scale.

That leaves the share price closely tied to future expectations.

Foolish Takeaway

This week’s pullback shows how quickly sentiment can shift with high-growth stocks.

4DMedical has clear potential, and its recent run shows how strong the upside can be. But it is still not profitable, which adds risk at current levels.

Personally, I would rather back a more established name like Pro Medicus Ltd (ASX: PME), which is already delivering consistent earnings.

4DMedical may have upside, but it comes with higher volatility and risk.

The post Why this ASX healthcare high-flyer just dropped another 9% today appeared first on The Motley Fool Australia.

More reading

• The ASX’s hottest shares just stumbled — warning sign?
• Here are the top 10 ASX 200 shares today
• 6 ASX 200 shares downgraded by brokers this week
• Here are the top 10 ASX 200 shares today
• What are experts saying about these red hot ASX 200 shares?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Plenty of ASX shares are in the process of releasing quarterly updates and results. 

After more reports and key announcements this week, the team at Morgans have provided fresh guidance on these ASX shares. 

Let’s see if Morgans sees these ASX shares as a buy, hold or sell. 

6K Additive Inc (ASX: 6KA)

6K Additive is a US-based manufacturer, upcycling metal scrap into premium metal powders and alloying additives.

Yesterday, the company released Quarterly Activities and Cash Flow Report. 

The team at Morgans said the company delivered a strong March quarter update, with revenue up 88% to US$6.2m. 

This implies an annualised run-rate of ~US$25m, up from ~US$22m in 4Q25, driven by solid demand from both new and existing customers. The run-rate is also ahead of our CY26 revenue forecast of US$22.8m, with the company capturing market share and improving operational metrics. B

oth the Powder (+100%) and Alloy (+70%) products divisions delivered strong revenue growth on the pcp, with a higher order backlog supporting sales momentum over coming months.

Based on this guidance, Morgans said it thinks the company is well positioned to benefit from strong demand in metal additive manufacturing and US initiatives to reshore critical minerals, supported by its fully domestic powder production which reduces reliance on foreign-controlled feedstock. 

The broker has retained its speculative buy rating and $1.30 price target on these ASX shares. 

This target is approximately 71% upside from today’s share price. 

Atlas Arteria Ltd (ASX: ALX)

This ASX company is a global owner, operator, and developer of toll roads. 

It received an unsolicited, off-market bid earlier this week from infrastructure investor IFM Investors.

This sent the stock price surging 14% higher on Monday. 

The team at Morgans said given IFM’s existing large (and growing) stake in ALX and the OTPP poison pill we believe it unlikely that a counter-bidder will emerge. 

Hence, our assessment is that risk at current prices is skewed to the downside ($4.22/share) rather than upside ($5.10/share). TRIM into current share price strength.

ALX shares are currently exchanging hands for $4.84. 

Imricor Medical Systems Inc (ASX: IMR)

Imricor is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures.

The company just released a 1Q26 cash flow report.

Morgans said while sales remain modest the underlying cash burn was higher than the previous quarter and expected to normalise around US$6m. 

During the quarter one-off costs related to the purchase of 40 generators which were part of an in-house transitioning process. Cash at the end of the quarter was US$32.9m, representing 5.5 quarters of underlying cash burn.

We have made no changes to forecasts. However, a higher risk-free rate (house view), sees our DCF valuation reduce to A$2.63 (was $2.71). We maintain our SPECULATIVE BUY recommendation with numerous catalysts approaching.

This indicates a 35% upside from today’s stock price of $1.94. 

The post Are these ASX shares a buy, hold or sell according to Morgans after key updates? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Why Atlas Arteria, Forrestania, Megaport, and WA1 shares are charging higher today
• Why the Atlas Arteria share price is rocketing 14% today
• Atlas Arteria receives a takeover offer
• This ASX dividend share could deliver a return of more than 25% Macquarie says

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Many of Australia’s top brokers have been busy adjusting their financial models and recommendations again. This has led to a number of broker notes being released this week.

Three ASX shares that brokers have named as buys this week are listed below. Here’s why their analysts are feeling bullish on them right now:

Life360 Inc. (ASX: 360)

According to a note out of the Macquarie equities desk, its analysts have initiated coverage on this location technology company’s shares with an outperform rating and $32.20 price target. The broker believes that recent share price weakness has created an asymmetrical risk profile for investors. It highlights that Life360’s shares are changing hands for only 23x estimated FY 2027 earnings. It thinks this is cheap for a company with such a strong revenue growth outlook, as well as operating leverage potential. The Life360 share price is trading at $20.31 on Wednesday afternoon.

Megaport Ltd (ASX: MP1)

A note out of Citi reveals its analysts have retained their buy rating on this network solutions company’s shares with an improved price target of $15.00. This follows the release of an update which revealed that Megaport’s Latitude business has won a significant contract. Megaport advised that it has secured a three-year compute and storage contract with a total value of approximately US$25.1 million (A$35.4 million). In response, the broker has upgraded its annual recurring revenue and EBITDA forecasts. And while it suspects that capital expenditure investment may have to increase, Citi isn’t concerned due to the attractive returns and payback profiles. The Megaport share price is fetching $9.05 at the time of writing.

Newmont Corporation (ASX: NEM)

Analysts at Ord Minnett have retained their buy rating and $205.00 price target on this gold miner’s shares. According to the note, the broker was impressed with Newmont’s performance during the first quarter. It notes that the company’s production came in ahead of expectations, which underpinned stronger than expected earnings and cash flow generation. The broker highlights that this has supported another increase in the gold miner’s share buyback program. In response, the team at Ord Minnett has lifted its earnings forecasts for FY 2026 to reflect the stronger than expected performance. The Newmont share price is trading at $154.06 on Wednesday.

The post Top brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Wednesday
• 6 ASX 200 shares with strengthened buy ratings this week
• What I’d do with $15,000 in ASX 200 shares right now
• 3 ASX 200 shares just upgraded to strong buy — here’s what the brokers are saying
• These ASX 200 shares could rise 25% to 70%

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Life360 and Megaport. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Macquarie Group, and Megaport. The Motley Fool Australia has positions in and has recommended Life360 and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.